Last reviewed · How we verify
Norpace Cr (Disopyramide Phosphate)
Norpace Cr (generic name: Disopyramide Phosphate) is a Type 1 antiarrhythmic Small molecule drug developed by Pfizer. It is currently FDA-approved (first approved 1977) for Ventricular arrhythmia.
Type 1 antiarrhythmic that decreases diastolic depolarization and increases action potential duration.
Norpace Cr is a small molecule drug that blocks the sodium channel alpha subunit, classified as a blocker. It is used to treat conditions such as atrial fibrillation, heart failure, and to improve quality of life, often in combination with other treatments like rate and rhythm control drugs, AV Node ablation, and device implant.
At a glance
| Generic name | Disopyramide Phosphate |
|---|---|
| Sponsor | Pfizer |
| Drug class | Type 1 antiarrhythmic |
| Target | Cardiac sodium channels; cardiac cells with augmented automaticity |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1977 |
Mechanism of action
Disopyramide phosphate is a Type 1 antiarrhythmic drug similar to procainamide and quinidine. In animal studies, it decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0), and increases the action potential duration of normal cardiac cells. It also decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors. In humans at therapeutic plasma levels, disopyramide phosphate shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has minimal effect on the effective refractory period of the AV node. It shows little effect on AV-nodal and His-Purkinje conduction times or QRS duration, though prolongation of conduction in accessory pathways occurs.
Approved indications
- Ventricular arrhythmia
Common side effects
- Headache
- Dizziness
- Diarrhoea
- Pain in extremity
- Paraesthesia
- Syncope
- Dry mouth
- Dyspepsia
- Fatigue
- Chest discomfort
- Complication associated with device
- Non-cardiac chest pain
Drug interactions
- Phenytoin and other hepatic enzyme inducers
- Other antiarrhythmic drugs (quinidine, procainamide, lidocaine, propranolol)
- Verapamil
- Clarithromycin and erythromycin
- Ketoconazole and other potent CYP3A4 inhibitors
- Quinidine
- Propranolol and diazepam
- Digoxin
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norpace Cr CI brief — competitive landscape report
- Norpace Cr updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Norpace Cr
What is Norpace Cr?
How does Norpace Cr work?
What is Norpace Cr used for?
Who makes Norpace Cr?
What is the generic name of Norpace Cr?
What drug class is Norpace Cr in?
When was Norpace Cr approved?
What development phase is Norpace Cr in?
What are the side effects of Norpace Cr?
What does Norpace Cr target?
Related
- Drug class: All Type 1 antiarrhythmic drugs
- Target: All drugs targeting Cardiac sodium channels; cardiac cells with augmented automaticity
- Manufacturer: Pfizer — full pipeline
- Indication: Drugs for Ventricular arrhythmia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing